Please wait while the formulary information is being retrieved.
ANORO ELLIPTA (UMECLIDINIUM BROMIDE/VILANTEROL TRIFENATATE)
- Bronchospasm prevention with COPD
- Prevention of bronchospasm with chronic bronchitis
- Prevention of bronchospasms with emphysema
62.5 mcg-25 mcg/actuation powder for inhalation
- Inhale 1 puff by inhalation route once daily at the same time each day
Bronchospasm prevention with COPD
- Inhale 1 puff by inhalation route once daily at the same time each day
Prevention of bronchospasm with chronic bronchitis
- Inhale 1 puff by inhalation route once daily at the same time each day
Prevention of bronchospasms with emphysema
- Inhale 1 puff by inhalation route once daily at the same time each day
- None
Contraindicated
- bromocriptine
- cabergoline
- Cafergot
- Compound 347
- Cycloset
- D.h.e.45
- dihydroergotamine
- enflurane
- ergoloid
- Ergomar
- ergotamine tartrate
- ergotamine-caffeine
- Forane
- isoflurane
- methylergonovine
- Migergot
- Migranal
- Parlodel
- pramlintide
- sevoflurane
- Sojourn
- Symlinpen 120
- Symlinpen 60
- Terrell
- Ultane
Severe
Moderate
- K-tab
- Klor-con
- Klor-con 10
- Klor-con M10
- Klor-con M15
- Klor-con M20
- Medi-lyte
- potassium chloride
- potassium citrate
- potassium Cl-calcium phos-mag
- sodium Cl-potassium chloride
- Thermotabs
- Urocit-k 10
- Urocit-k 15
- Urocit-k 5
- Acutely deteriorating asthma
- Congenital long QT syndrome
Contraindicated
- Chronic myocardial ischemia
- Hypokalemia
- Prolonged QT interval
Severe
Moderate
- Angle-closure glaucoma
- Benign prostatic hyperplasia
- Bladder outflow obstruction
- Cardiac arrhythmia
- Diabetes mellitus
- Hypertension
- Seizure disorder
- Thyrotoxicosis
- Urinary retention
ANORO ELLIPTA (UMECLIDINIUM BROMIDE/VILANTEROL TRIFENATATE)
- Bronchospasm prevention with COPD
- Prevention of bronchospasm with chronic bronchitis
- Prevention of bronchospasms with emphysema
- None
- Arthralgias
- Cough
- Headache disorder
- Pharyngitis
- Upper respiratory infection
More Frequent
Severe
Less Severe
- Urinary retention
- Chest pain
- Constipation
- Cough
- Diarrhea
- Dyspepsia
- Influenza
- Lower respiratory infection
- Muscle spasm
- Myalgias
- Nasal congestion
- Neck pain
- Nervousness
- Pain
- Palpitations
- Pharyngitis
- Tachycardia
- Toothache
- Tremor
- Upper abdominal pain
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal ECG
- Anaphylaxis
- Angioedema
- Atrial fibrillation
- Bronchitis
- Cardiac arrhythmia
- Chest pain
- Extrasystoles
- Hyperglycemia
- Hypersensitivity drug reaction
- Hypertension
- Hypokalemia
- Paradoxical bronchospasm
- Secondary angle-closure glaucoma
- Sinusitis
- Supraventricular premature beats
- Supraventricular tachycardia
- Upper respiratory infection
Less Severe
- Arthralgias
- Blurred vision
- Conjunctivitis
- Dysgeusia
- Dysuria
- Fever
- Oral candidiasis
- Peripheral edema
- Pruritus of skin
- Skin rash
- Symptoms of anxiety
- Urticaria
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Umeclidinium, Vilanterol
Not indicated in pediatrics or for asthma. Used for COPD maintenance.
- 1 Day – 18 Years
- Not indicated in pediatrics or for asthma. Used for COPD maintenance.
Umeclidinium
- Severity Level:
2
- Additional Notes: Insufficient human data available
Vilanterol
- Severity Level:
C
- Additional Notes: Insufficient human data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Umeclidinium
Insufficient human data; excreted in rats
Insufficient data for vilanterol; other beta-agonists are excreted in milk
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data; excreted in rats |
Vilanterol (inhal)
Insufficient human data; excreted in rats
Insufficient data for vilanterol; other beta-agonists are excreted in milk
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data for vilanterol; other beta-agonists are excreted in milk |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Umeclidinium
Urogenital-Use caution in men with benign prostatic hyperplasia; may decrease urinary flow and cause urinary retention. Other-Use caution in elderly with narrow angle glaucoma. Gastrointestinal-Anticholinergic effects may worsen constipation in predisposed elderly.
Cardiovascular-Use caution in severe cardiovascular diseases, particularly coronary insufficiency, since beta-agonists increase heart rate and blood pressure. Endocrine-Use caution in poorly controlled diabetes or hyperthyroidism.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: Y
Vilanterol
Urogenital-Use caution in men with benign prostatic hyperplasia; may decrease urinary flow and cause urinary retention. Other-Use caution in elderly with narrow angle glaucoma. Gastrointestinal-Anticholinergic effects may worsen constipation in predisposed elderly.
Cardiovascular-Use caution in severe cardiovascular diseases, particularly coronary insufficiency, since beta-agonists increase heart rate and blood pressure. Endocrine-Use caution in poorly controlled diabetes or hyperthyroidism.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- One ingredient in this product is vilanterol. It belongs to the class of drugs known as long-acting beta agonists (LABAs). Rarely, people with asthma who use LABA medications have had serious (sometimes fatal) asthma-related breathing problems. Umeclidinium/vilanterol is not approved to treat asthma.
| Bronchospasm prevention with COPD | |
| J44 | Other chronic obstructive pulmonary disease |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| Prevention of bronchospasm with chronic bronchitis | |
| J41 | Simple and mucopurulent chronic bronchitis |
| J41.0 | Simple chronic bronchitis |
| J41.1 | Mucopurulent chronic bronchitis |
| J41.8 | Mixed simple and mucopurulent chronic bronchitis |
| J42 | Unspecified chronic bronchitis |
| J44 | Other chronic obstructive pulmonary disease |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| Prevention of bronchospasms with emphysema | |
| J43 | Emphysema |
| J43.0 | Unilateral pulmonary emphysema [macleod's syndrome] |
| J43.1 | Panlobular emphysema |
| J43.2 | Centrilobular emphysema |
| J43.8 | Other emphysema |
| J43.9 | Emphysema, unspecified |
| J44 | Other chronic obstructive pulmonary disease |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| 0-9 | A-Z |
|---|---|
| J41 | Simple and mucopurulent chronic bronchitis |
| J41.0 | Simple chronic bronchitis |
| J41.1 | Mucopurulent chronic bronchitis |
| J41.8 | Mixed simple and mucopurulent chronic bronchitis |
| J42 | Unspecified chronic bronchitis |
| J43 | Emphysema |
| J43.0 | Unilateral pulmonary emphysema [macleod's syndrome] |
| J43.1 | Panlobular emphysema |
| J43.2 | Centrilobular emphysema |
| J43.8 | Other emphysema |
| J43.9 | Emphysema, unspecified |
| J44 | Other chronic obstructive pulmonary disease |
| J44 | Other chronic obstructive pulmonary disease |
| J44 | Other chronic obstructive pulmonary disease |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
| J44.9 | Chronic obstructive pulmonary disease, unspecified |
Formulary Reference Tool